CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical
devices and related software solutions, announced today that more than 50,000
patients at high risk of sudden cardiac arrest (SCA) have been prescribed the LifeVest® Wearable Defibrillator.

The LifeVest is worn by patients at risk for SCA, providing
protection during their changing condition and while permanent SCA risk has not
been established. The LifeVest allows a patients physician time to assess his
or her long-term arrhythmic risk and make appropriate plans.

The LifeVest is lightweight and easy to wear, allowing
patients to return to their activities of daily living, while having the peace
of mind that they are protected from SCA. The LifeVest continuously monitors
the patients heart and, if a life-threatening heart rhythm is detected, the
device delivers a treatment shock to restore normal heart rhythm.

“As an investigator in the original WEARIT/BIROAD clinical
trial and the primary investigator for the WEARIT II registry, it is rewarding
to see so many patients have benefited from this therapy. The LifeVest plays an
important role in the continuum of care for patients at high risk from SCA”,
stated Arthur J. Moss, M.D., University of Rochester Medical Center. “LifeVest
allows physicians to protect patients during their period of highest risk early
after an acute cardiac event such as a myocardial infarction or newly diagnosed
nonischemic cardiomyopathy, when other therapies are not appropriate due to the
patients changing condition and the potential for cardiac recovery.”

“The fact that over 50,000 patients have been prescribed the
LifeVest by their physicians is a meaningful milestone, made even more
rewarding by the fact that it was reached during Sudden Cardiac Arrest
Awareness Month. The powerful result of partnering with physicians to protect
so many patients from SCA is that all of these patients benefit from the peace
of mind provided by the protection and a patients life is being saved almost
each and every day by a ZOLL LifeVest,” said Richard A. Packer, Chief Executive
Officer of ZOLL.

The LifeVest is used for a wide range of patient conditions
or situations, including following a heart attack, before or after bypass
surgery or stent placement, as well as for those with cardiomyopathy or
congestive heart failure that places them at particular risk.

The LifeVest is covered by most health plans in the United States,
including commercial, state, and federal plans.

For more information, go to www.zoll.com or call 1-800-543-3267.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and related
software solutions that help advance emergency care and save lives, while
increasing clinical and operational efficiencies. With products for
defibrillation and monitoring, circulation and CPR feedback, data management,
fluid resuscitation, and therapeutic temperature management, ZOLL provides a
comprehensive set of technologies that help clinicians, EMS
and fire professionals, and lay rescuers treat victims needing resuscitation
and critical care.

A NASDAQ Global Select company and a Forbes 100 Most
Trustworthy Company for the past three years, ZOLL develops and manufactures
its products in the United States, in California, Colorado, Illinois,
Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and
service representatives, 1,100 business partners, and 200 independent
representatives serve our customers in over 140 countries around the globe. For
more information, visit www.zoll.com.